PBM Reform Momentum: How FTC Scrutiny Is Reshaping $600B in Drug Pricing.

Drug Pricing TransparencyPBM FTC InvestigationPBM ReformPharmacy Manager Benefit FTC

This report explores the impact of increased FTC scrutiny and legislative reforms on the U.S. Pharmacy Benefit Manager (PBM) industry, specifically focusing on drug pricing between 2026 and 2030. The document details significant changes driven by federal actions, aiming to enhance transparency and reduce costs through standardized practices such as rebate pass-throughs. Key reforms include the 2026 Consolidated Appropriations Act, influencing stakeholder dynamics across markets and sectors. The report evaluates economic impacts, competition, market restructuring, and outlines strategic policy recommendations for sustained improvement in drug pricing practices.

Researcher

Parthiban Paramasivam, Ghost Research

PublishedMarch 2026

Perspective.

PurposeTo analyze the impact of FTC scrutiny and legislative actions on drug pricing reform.

AudiencePolicy makers, healthcare administrators, pharmaceutical industry stakeholders.

Special EmphasisPolicy reform, transparency, economic impacts.

89Pages of Deep Analysis

90Curated Credible Sources

12Proprietary AI Visuals

19Data Analysis Tables

$495

Parthiban Paramasivam

5+ Years of Experience

Sectors & Industries

HealthCare

Functions & Expertise

Healthcare & Life SciencesContent & Communication

Have questions? Our Research Desk is here to help

Top Insights.

FTC scrutiny and reforms aim to enhance transparency and reduce drug costs.Reforms are driven by the Consolidated Appropriations Act 2026.Economic impacts include changes in pricing incentives and market structure.Policy recommendations focus on measurable transparency and oversight.

Key Questions Answered.

89Pages of Deep Analysis

12Proprietary AI Visuals

90Curated Credible Sources

19Data Analysis Tables

Summary.

FTC scrutiny and legislative reforms in the U.S. PBM industry aim to deliver $7 billion in savings over ten years by mandating transparency and 100% rebate pass-through by 2029. This shift targets markup inflation and anticompetitive practices, significantly affecting costs and market dynamics.

Emerging trends indicate enhanced market transparency and constraints on PBM revenue streams, promoting cost-plus models. The strategic focus is on compliance with new federal mandates, potentially reshaping drug pricing structures by strengthening independent pharmacies and increasing affordability across U.S. healthcare markets.

PBM Reform Momentum: How FTC Scrutiny Is Reshaping $600B in Drug Pricing.

Perspective.

Parthiban Paramasivam

1What is the primary purpose of the report?

2Which act is central to the reforms discussed in the report?

3Who are the primary audiences for the report?

4What geographic area does the report mainly focus on?

5What are the main themes of the report?

Summary.